UroGen Pharma URGN
NASDAQ URGN
$41.40 +0.85 (+2.10%)
At close: Oct 2, 2026 · 4:00 PM EDT

UroGen Pharma (URGN) Selling, General & Administrative (2017 - 2026)

Updated

UroGen Pharma (URGN) posted Selling, General & Administrative of $48.44 million for Q2 2026, up 12.1% from $43.2 million a year earlier but down 5.9% from the prior quarter.

Analysis

UroGen Pharma (URGN) Selling, General & Administrative (2017 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Selling, General & Administrative at UroGen Pharma was $176.85 million, up 24.6% year-over-year; for FY2025, it came in at $155.1 million, up 28.0% from FY2024.

  • Annual Selling, General & Administrative has increased for three consecutive years, with a five-year compound annual growth rate of 11.4% (FY2020 to FY2025).
  • In prior years, UroGen Pharma's Selling, General & Administrative was $121.15 million in FY2024 (+29.9%), $93.27 million in FY2023 (+12.6%), $82.84 million in FY2022 (-5.4%) and $87.54 million in FY2021 (-3.0%).
  • Quarterly Selling, General & Administrative has run from a low of $19.07 million in Q3 2022 to a high of $51.49 million in Q1 2026 over five years.
  • On a year-over-year basis, Selling, General & Administrative has increased in each of the last 15 quarters, with growth averaging 31.1% over the last eight quarters.
  • The strongest year-over-year quarter for Selling, General & Administrative in the past five years was Q1 2026, with growth of 47.2%; the weakest was Q3 2022, with a decline of 11.8%.
  • According to Business Quant data, Selling, General & Administrative for the three prior quarters was $51.49 million (Q1 2026), $39.35 million (Q4 2025) and $37.58 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) SG&A (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn 3.43 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn 6.43 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn 3.63 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn 2.90 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn -3.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn -5.65 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn 1.75 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn 1.92 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn 3.41 Bn
10 UroGen Pharma 2.02 Bn 1.53 Bn 65.88 Mn 48.44 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 48.44 Mn
Mar 31, 2026 51.49 Mn
Dec 31, 2025 39.35 Mn
Sep 30, 2025 37.58 Mn
Jun 30, 2025 43.20 Mn
Mar 31, 2025 34.97 Mn
Dec 31, 2024 34.86 Mn
Sep 30, 2024 28.94 Mn
Jun 30, 2024 30.06 Mn
Mar 31, 2024 27.30 Mn
Dec 31, 2023 24.55 Mn
Sep 30, 2023 21.76 Mn
Jun 30, 2023 22.49 Mn
Mar 31, 2023 24.47 Mn
Dec 31, 2022 21.63 Mn
Sep 30, 2022 19.07 Mn
Jun 30, 2022 20.83 Mn
Mar 31, 2022 21.30 Mn
Dec 31, 2021 21.42 Mn
Sep 30, 2021 21.62 Mn
API Access

UroGen Pharma Selling, General & Administrative API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=selling-general-and-administrative&ticker=URGN&period=max&api_key=YOUR_API_KEY